In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type 1 selected

Type

Guidance programme 7 selected

Guidance programme

Showing 1 to 10 of 10

TitleConsultationTypeConsultation end date
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liverDraft scope consultationInterventional procedures guidance
In-situ normothermic regional perfusion of the abdomen for donor livers following circulatory deathDraft scope consultationInterventional procedures guidance
Tarlatamab for treating small-cell lung cancer that has progressed after platinum-based chemotherapy ID6617Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]Draft guidanceTechnology appraisal guidance
Pharmalgen for the treatment of bee and wasp venom allergyReview proposal consultationTechnology appraisal guidance
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphomaReview proposal consultationTechnology appraisal guidance
Guidance on the use of electroconvulsive therapyReview proposal consultationTechnology appraisal guidance
Pharmalgen for the treatment of bee and wasp venom allergyReview proposal consultationTechnology appraisal guidance
Artificial intelligence software to help detect and characterise colorectal polypsDiagnostics consultationDiagnostics guidance
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All